Home
Orphan Drugs & Rare Diseases
14 October - 15 October 2013
Orphan Drugs & Rare Diseases

SAE Media Group are pleased to announce its second annual Orphan Drugs & Rare Diseases conference due to meet on the 14 & 15 October 2013, in London. Recent years have been a time of huge growth in orphan drug development, but also a time of increased pressure as many leading blockbuster drugs soon come off patent. SAE Media Group's orphan drugs conference will allow a specific focus on the current rare diseases drug development landscape, and where recent research will be touching upon going into the future.


Join the world leading expert speaking faculty and gain a wide ranging, highly inclusive view on the orphan drug industry as it currently stands. Speakers will highlight cutting edge research via case studies taking place in previously untreatable patients. Current regulatory policies involving the FDA & EMA, new drug discoveries and partnerships in clinical trials and drug development with patient groups.

A 'big pharma spotlight session' will be held on the morning of the 14th highlighting where current pipelines stand and where exactly the next succesful drug will be treating rare diseases. We will also be discussing HTA and pricing issues that are currently being implemented after recent reforms in Europe.
 

FEATURED SPEAKERS

Adrien Lemoine

Adrien Lemoine

Director, Strategy & Operations, GlaxoSmithKline Rare Diseases
David King

David King

Director, Regulatory Policy and Intelligence, Novo Nordisk
Estelle de Barbeyrac

Estelle de Barbeyrac

Regulatory Affairs, Genethon
Panos Kanavos

Panos Kanavos

Reader in International Health Policy, London School of Economics
Tony Hall

Tony Hall

Co-Founder, Findacure Foundation

Adrien Lemoine

Director, Strategy & Operations, GlaxoSmithKline Rare Diseases
Adrien Lemoine

Anders Waas

Chief Executive Officer, Tikomed
Anders Waas

Bertram Häussler

Chairman of the Board of Management, IGES Institut
Bertram Häussler

Camille Métais

Sr Regulatory Affairs Manager, Alexion Pharmaceuticals
Camille Métais

David King

Director, Regulatory Policy and Intelligence, Novo Nordisk
David King

Deborah A. O'Neil

Chief Executive & Scientific Officer,, NovaBiotics Ltd
Deborah A. O'Neil

Dominic Atkins

Global Business Development Director Clinigen Global Access Programs (GAP), Clinigen GAP
Dominic Atkins

Donald Macarther

Global Pharmaceutical Business Analyst, Justpharmareports
Donald Macarther

Estelle de Barbeyrac

Regulatory Affairs, Genethon
Estelle de Barbeyrac

Fernando Royo

VP, Intl. Government Affairs, Genzyme
Fernando Royo

Genevieve Michaux

Counsel, Hunton & Williams
Genevieve Michaux

Gregory LaRosa

Senior Director, Rare Disease Research Unit, Pfizer
Gregory LaRosa

Karl Petrovsky

Senior Manager - Industry Affairs, Baxter
Karl Petrovsky

Kate Bushby

Professor of Neuromuscular Genetics, University Of Newcastle
Kate Bushby

Oliver Timmis

Communications Project Manager, AKU Society
Oliver Timmis

Panos Kanavos

Reader in International Health Policy, London School of Economics
Panos Kanavos

Tony Hall

Co-Founder, Findacure Foundation
Tony Hall

Conference agenda

clock

9:00

Registration & Coffee

clock

9:30

Welcome & An introduction to Orphan Drugs

clock

10:15

Guide to writing an orphan designation application (EU & US)

clock

11:15

Morning Coffee

clock

11:45

Designing clinical trials for Orphan Drugs

clock

12:30

Registries for rare diseases

clock

13:15

Lunch

clock

14:00

Rare diseases from the perspective of a patient group

clock

14:45

Market access and reimbursement for orphan drugs

clock

15:30

Q & A Session and Conclusion of workshop

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Tony Hall

Tony Hall, Co-Founder, Findacure Foundation

clock

9:10

Rare disease research at Pfizer - A spotlight

Gregory LaRosa

Gregory LaRosa, Senior Director, Rare Disease Research Unit, Pfizer

  • Overview of research strategy
  • Pipeline highlights
  • Case studies of Pfizers current work
  • clock

    9:50

    De-risking rare diseases drugs development and commercialisation

    Adrien Lemoine

    Adrien Lemoine, Director, Strategy & Operations, GlaxoSmithKline Rare Diseases

  • Misconceptions about the rare disease industry
  • Innovative business models to minimize development and commercial risks
  • Franchises
  • Value-based pricing
  • Partnerships   
  • Case study: venture capital fund dedicated to rare diseases
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Orphan drugs and healthcare systems sustainability: Myths, challenges & opportunities

    Fernando Royo

    Fernando Royo, VP, Intl. Government Affairs, Genzyme

  • Current and foreseeable expenditure in orphan drugs
  • Compounding factors
  • The different perspectives on the value of orphan drugs
  • Initiatives for sustainable yet equitable access
  • clock

    11:40

    HTA Assessment in Orphan Drugs

    Panos Kanavos

    Panos Kanavos, Reader in International Health Policy, London School of Economics

  • HTA Reviews in Orphan Drugs
  • Value based pricing in a regulatory setting
  • Platforms for collaboration and harmonization
  • Case study
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Improving service delivery for rare diseases and delivering new therapies: what is the role of the EUCERD?

    Kate Bushby

    Kate Bushby, Professor of Neuromuscular Genetics, University Of Newcastle

  • The process of national plans for RD
  • Centres of expertise and European Reference Networks
  • How these structures may support therapy development and delivery
  • Case study
  • clock

    14:00

    Early access for orphan drugs: An essential part of market access strategy

    Dominic Atkins

    Dominic Atkins, Global Business Development Director Clinigen Global Access Programs (GAP), Clinigen GAP

    Patients suffering from orphan diseases are very aware of products in development and demand early access. This presentation will give examples of successful global access programs, as well as addressing the challenges, pitfalls and opportunities of early access.

    clock

    14:40

    Afternoon Tea

    clock

    15:10

    Where European Payers Push Back on Prices and Funding for Orphan Drugs

    Donald Macarther

    Donald Macarther, Global Pharmaceutical Business Analyst, Justpharmareports

  • HTA and payer bodies views on orphan drugs
  • Why reimbursement is sometimes refused
  • How market entry agreements and patient registries can help
  • Case studies from across Europe
  • clock

    15:50

    Orphan Drugs in Germany

    Bertram Häussler

    Bertram Häussler, Chairman of the Board of Management, IGES Institut

  • Regulatory and Political Environment
  • Market and Budget Impact
  • Future Developments
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Tony Hall

    Tony Hall, Co-Founder, Findacure Foundation

    clock

    9:10

    How regulatory strategy can help to optimize Orphan drugs development?

    Camille Métais

    Camille Métais, Sr Regulatory Affairs Manager, Alexion Pharmaceuticals

  • What are the available procedures to optimize drug development and in particular orphan drugs development?
  • What are the regulatory hurdles to develop and register an orphan drug?
  • What is coming next? Will this address the current hurdles
  • clock

    9:50

    Regulatory challenges of ex-vivo gene therapy medicinal products for rare diseases

    Estelle de Barbeyrac

    Estelle de Barbeyrac , Regulatory Affairs, Genethon

  • Pharmaceutical requirements for genetically-modified cell-based medicinal products and constraints associated with very rare patients’ populations
  • Flexibility versus standardization of the manufacturing process for small scale productions
  • Possible impact on the data set available for registration
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Global developments in orphan drug and rare disease legislation

    David King

    David King, Director, Regulatory Policy and Intelligence, Novo Nordisk

  • Recent trends in orphan drug legislation
  • Future perspectives over the next few years
  • Case study
  • clock

    11:40

    Lynovex®, a novel multi-acting therapeutic orphan drug candidate for the treatment of cystic fibrosis

    Deborah A. O'Neil

    Deborah A. O'Neil, Chief Executive & Scientific Officer,, NovaBiotics Ltd

  • Lynovex® as a first-in-class, wholly novel, differentiated approach to tackling cystic fibrosis
  • Mucoactive, antibacterial & antibiofilm properties
  • Repositioning an existing therapeutic agent for CF against a background of proven safe historical use in other conditions
  • Lynovex’s interactions with and potential clinical impact on the existing armoury of CF antibiotics
  • One tri-functional active compound, two (or more) potential routes of delivery
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Findacure Foundation

    Tony Hall

    Tony Hall, Co-Founder, Findacure Foundation

    Fundamental diseases
    Lack of commercial viability for many rare diseases
    Can a non-commercial approach address this unmet need?

    clock

    14:00

    Opportunities and challenges for biotech company to develop Orphan Drugs

    Anders Waas

    Anders Waas, Chief Executive Officer, Tikomed

  • Strategy and tactics on the way – building a pipeline
  • Effective drug development and research
  • Partnering focus and timing of deals
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    A Patient Group's perspective on patient recruitment and retention

    Oliver Timmis

    Oliver Timmis, Communications Project Manager, AKU Society

  • Patient recruitment in Europe
  • How to maximise patient retention
  • Why patient groups can be an effective may to manage the patient input of clinical trials
  • clock

    15:50

    Regulatory Protection for Orphan Medicinal Products

    Genevieve Michaux

    Genevieve Michaux, Counsel, Hunton & Williams

  • Market exclusivity
  • Data exclusivity
  • Paediatric incentives
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two


    Director, Regulatory Policy and Intelligence
    Novo Nordisk
    Senior Director, Rare Disease Research Unit
    Pfizer
    Global Pharmaceutical Business Analyst
    Justpharmareports
    Sr Regulatory Affairs Manager
    Alexion Pharmaceuticals
    Regulatory Affairs
    Genethon
    Chairman of the Board of Management
    IGES Institut
    VP, Intl. Government Affairs
    Genzyme
    Counsel
    Hunton & Williams
    Senior Manager - Industry Affairs
    Baxter
    Chief Executive & Scientific Officer,
    NovaBiotics Ltd
    Communications Project Manager
    AKU Society
    Chief Executive Officer
    Tikomed
    Professor of Neuromuscular Genetics
    University Of Newcastle
    Co-Founder
    Findacure Foundation
    Director, Strategy & Operations
    GlaxoSmithKline Rare Diseases
    Reader in International Health Policy
    London School of Economics
    Global Business Development Director Clinigen Global Access Programs (GAP)
    Clinigen GAP

    Workshops

    Applications for development of Orphan Drugs

    Applications for development of Orphan Drugs

    Marriott Regents Park
    16 October 2013
    London, United Kingdom

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.